Fellows Poster

(8-011) Impact of Glucagon-Like Peptide-1 (GLP-1) Therapy Discontinuation on Clinical Outcomes and Healthcare Utilization

(8-012) Impact of Reduced Copays on Primary Non-Adherence of Inhalers in Patients with Asthma and/or COPD in an Employee Health Plan: An Interrupted Time Series Analysis

(8-013) Impact of an Outpatient Rifaximin Access Program on 30-Day Readmission Rates in Hepatic Encephalopathy Patients Initiated on Rifaximin in the Inpatient Setting

(8-015) Pharmacy Turns to Care: An Ethnography of the Shift from Product Dispensing to Comprehensive Patient-Centered Services in the US

(8-017) Pharmacist role on postoperative pain management at admission and discharge

(8-018) An Open-Label, Phase I, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fexofenadine Topical Lotion 1% in Normal Healthy Volunteers

(8-019) Third-Year Pharmacy Student Self-Perceived Knowledge and Confidence in Three Pharmacist-Managed Medications

(8-020) Medication Adherence to Osimertinib in Patients with Non-Small Cell Lung Cancer

(8-024) Evaluation of the stability of a dexamethasone intravenous infusion used for postoperative nausea and vomiting prophylaxis.

(8-026) Galenic Validation and Clinical Experience of a Roflumilast 0.166mcg/g Ointment in Orobase for Treatment of Persistent Oral Aphthous Ulcers

(8-030) Racial and Ethnic Representation in Global Phase 3 Clinical Trials for Type 2 Diabetes Medications (2020-2024)

(8-031) A Literature Review of the Underrepresentation of Hispanics in Clinical Trials

(8-032) Evaluating the Effect of a Multi-Cultural Calendar on Faculty Scheduling

(8-033) Pharmacy Advances Clinical Trials (PACT) Network to Achieve Diversity in COVID Clinical Trials: A Strategic Framework

(8-034) Landscape of Clinical Trial Diversity in Patients with Heterozygous Familial Hypercholesterolemia (HeFH): Findings and Future Perspectives

(8-035) Evaluating the Accuracy of Three Artificial Intelligence Models to Answer Drug Information Questions in Comparison to Drug Information Pharmacist-Curated Responses

(8-036) Patient Factors Associated with Buprenorphine versus Methadone Use on a Pharmacist-Integrated Inpatient Opioid Use Disorder Medication-Assisted Recovery Consult Service

(8-037) Real-World Efficacy and Safety of Biologic Therapy in Patients with Uncontrolled Severe Asthma

(8-039) Assessing Appropriateness of Antibiotic Prescribing for Urinary Tract Infections (UTIs) and Bacteriuria in the Outpatient Setting

(8-042) New therapeutic alternatives in graft versus host disease prophylaxis: abatacept

(8-044) Comparing Efficacy and Safety of Adalimumab and Etanercept in Ankylosing Spondylitis (AS): A Local Hospital Data

(8-045) Mortality and Hospitalization Rate of Heart Failure Patients with Preserved Ejection Fraction Treated with Dapagliflozin vs. Empagliflozin

(8-046) Medication Use Evaluation (MUE): Evaluating the Appropriateness of Orders for High-dose Sliding Scale Insulin within a Health System

(8-054) ASP-eXpert: Curbing antimicrobial resistance, improving clinical outcomes

(8-057) Doxycycline post-exposure prophylaxis for sexually transmitted infections in high-risk patients with or without HIV

(8-061) Three Days of Ceftriaxone for Uncomplicated Urinary Tract Infections Compared to Longer Durations of Therapy

(8-064) Descriptive Report: Utilizing Public Data Sources to Identify Unmet HIV Prevention Needs and PrEP Equity Gaps

(8-065) Digital Health Innovations in Cardiovascular Clinical Trials: Assessing Apple Watch as a Sensor-Based Digital Health Technology for Atrial Fibrillation

(8-068) Backing Up the Feed: Evaluating Feedback Opportunities on Corporate and Medical Information Websites Among Pharmaceutical Companies

(8-070) Applications of Artificial Intelligence (AI) and Machine Learning (ML) Methods in Oncology Clinical Trial Enrollment: A Literature Review

(8-072) Social Media Trends for Medical Affairs Content Within the Pharmaceutical Industry

(8-073) Student Voices: Exploring the Impact of Artificial Intelligence on Pharmacy Students

(8-074) Customization of Field-Facing Medical Affairs Resources: A Feasibility Assessment

(8-075) Preclinical Evaluation of CLX-155A, a Prodrug Conjugate of 5-FU and Valproic Acid, in a Foxn1 Athymic Nude Mouse Colorectal Cancer Model

(8-076) Analysis of the FDA Drug Induced Liver Injury Dataset: Comprehensive Review of the Hepatotoxicity Profile of Antineoplastic Agents and Implications for Drug Development

(8-077) Physicochemical stability study of furosemide in hypertonic saline solution using high-performance liquid chromatography

(8-078) Development and Validation of an Analytical Method by HPLC to Study the Physicochemical Stability of Drug Mixtures Used in Palliative Sedation Infusions

(8-080) Comprehensive Review of Immunotherapeutic Mechanisms of Actions in Global Phase II and III Advanced Biliary Tract Cancer Trials

(8-081) Effectiveness and Safety of Thrombopoietin Receptor Agonists for Persistent Thrombocytopenia Following CAR-T Therapy: A Retrospective Study and Analysis of Predictive Factors

(8-082) Identifying Barriers to Timely Initiation of Oral Anti-Cancer Therapy in Lung Cancer Patients

(8-083) An Examination of Alternative Payment Models (APMs) and Access of Novel Oncology Products

(8-084) Multivariate Analysis of Primary Resistance in Metastatic Colorectal Cancer with EGFR(+), Ras Wild-type, Chemotherapy with mFOLFOX or FOLFIRI combined with Bevacizumab/Cetuximab a Single Medical Institution

(8-089) Factors Affecting Trial Enrollment Rate in Radiopharmaceutical Clinical Trials

(8-091) Evaluation of Trends in Endpoints used in Clinical Trials for Metastatic Prostate Cancer

(8-095) Impact of mental health and substance use disorders on treatment outcomes in adolescents and young adults with opioid use disorder

(8-097) Optimization of psychiatric treatment using pharmacogenetics and comprehensive treatment assessment: program design and early results

(8-098) Should Adolescents Be Considered Adults for Tuberculosis Drug Dosing? An Evaluation of Pharmacokinetic Data Across Pediatric, Adolescent, and Adult Populations

(8-099) Trends in FDA OPDP and APLB Warning and Untitled Letters From 2017-2024 with Ad-hoc Analysis from 2011-2016

(8-100) Impact of Rolling Submissions on United States Food and Drug Administration (FDA) Review Times for Breakthrough Designation Drugs (2013-2023): A Quantitative Analysis

(8-101) The 340B Drug Pricing Program: Past, Present and Future Impacts on U.S. Healthcare Policy

(8-103) Food and Drug Administration Original Application Approval Timelines for Oncology and Hematology Products: An Analysis of Trends from 2013 to Present

(8-105) Impact of Early Exposure to Pharmaceutical Industry Career Paths in PharmD Students

(8-106) Predictors of Academic Progression and NAPLEX Success Among PharmD Students

(8-108) An Overview of Medical Affairs Pharmaceutical Fellowship Programs

(8-110) Retrospective Review of Scholarship Activities Conducted by Post-PharmD Biopharmaceutical Fellows

(8-111) Exploring the Diversity of 24 Character Strengths Across Functional Areas: Insights from the MCPHS Fellowship Program

(8-112) Bridging the Gap: Assessing the Value and Industry Perception of PharmD Fellowships in Biopharmaceutical Careers

(8-116) Comparison of Parkinson’s Disease-Specific and Non-Specific Pharmaceutical Interventions in Medication Reconciliation for Hospitalized Parkinson’s Patients

(8-117) Potential Role of Inflammation in Depression: A Literature Review

(8-120) Pharmacists and Pharmacy Availability and Its Relationship to Medically Underserved and Health Professional Shortage Areas in New York

(8-121) Pharmacovigilance in Clinical Practice: Trends in Pharmacist Safety Report Submissions

(8-122) Unraveling the Trends and Implications of Drug Withdrawals from the US Market

(8-128) Need for Speed: An Investigation into Online Demand, Health Hazards, and Notable Incidents of Substandard and Falsified Adderall

(8-130) Assessment of Duke University Health System inpatient fidaxomicin medication access process for enhanced guideline-directed fidaxomicin use for recurrent Clostridium difficile infection.

(8-131) Compliance and Optimization of the Eculizumab and Ravulizumab Risk Evaluation and Mitigation Strategy (REMS) Program Within a Multi-Hospital Health System in New Jersey

(8-138) Artificial Intelligence Platform for Automated Assessment of Quality of Life and Functional Capacity in Colorectal Cancer Patients. eB2-Mindcare Project

(8-139) Performing a Program Evaluation to Pilot an Interdisciplinary Surveillance Service to Improve the Acceptance of Tobacco Cessation via Telemedicine

(8-142) A Benchmark Survey of “Impostor Syndrome” in Pharmacy Students, Post-doc PharmD Industry Fellows, and Post-doc PharmD Residents

(8-143) Health Literacy Universal Precautions: An Evaluation of the Methods and Resources Utilized by Pharmacists to Aid in Bridging the Health Literacy Gap